Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

ctively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communic
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... BELLINGHAM, Washington, USA (PRWEB) May 26, 2015 ... a formal partnership with the Max Planck Society ... Extreme and Quantum Photonics. The center will link two ... of photonics, and will be only the third Max ... SPIE, the international society for optics and photonics, ...
(Date:5/26/2015)... HILDEN, Germany , May 26, ... QGEN ; Frankfurt Prime Standard: QIA) today ... Insight ® (QCI™) bioinformatics content and software ... report on genomic variants identified in next-generation sequencing ... bioinformatics platform are in oncology, for somatic and ...
(Date:5/26/2015)... Miami, FL (PRWEB) May 26, 2015 ... training, Inc. have announced plans for the company’s first ... 9, 2015, followed by a full day, hands-on stem ... hosted by J. Victor Garcia Gimenez, M.D., President of ... to the medical community’s increasing interest in regenerative medicine ...
(Date:5/26/2015)... 2015 Leading Regenerative Veterinary Medicine® ... long-term relationship with Veterinary Growth Partners, a membership ... to provide access to vital services to veterinary ... VGP as a dedicated partner in bringing stem ... Concentrating and using stem cells natural abilities to ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3
... gotten the law wrong. Why should ... we trust them to get cures right?, ST. ... opponents of stem cell cures refiled,their measure yet again, the third ... of Missouri Coalition for Lifesaving Cures, "In,their zeal to repeal stem ...
... Audio Webcast Friday, September 7, 2007, SAN DIEGO, ... announced today that Neurocrine Biosciences will,present at the Thomas ... September 7, 2007 at 11:30 a.m. Eastern,Time (ET) /8:30 ... and may be accessed on the Company,s website at, ...
... 99% Year-Over-Year, SHANGHAI, China, Sept. 5 ... WX ) ("WuXi PharmaTech" or "the Company"), ... development,outsourcing company, today announced its unaudited financial ... 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
Cached Biology Technology:3 strikes, you're out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause 2WuXi PharmaTech Announces Second Quarter 2007 Results 2WuXi PharmaTech Announces Second Quarter 2007 Results 3WuXi PharmaTech Announces Second Quarter 2007 Results 4WuXi PharmaTech Announces Second Quarter 2007 Results 5WuXi PharmaTech Announces Second Quarter 2007 Results 6WuXi PharmaTech Announces Second Quarter 2007 Results 7WuXi PharmaTech Announces Second Quarter 2007 Results 8WuXi PharmaTech Announces Second Quarter 2007 Results 9WuXi PharmaTech Announces Second Quarter 2007 Results 10
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... standard practice of giving infants and children 100 percent ... may actually inflict additional harm, researchers at UT Southwestern ... oxygen deprivation, known as hypoxic-ischemic brain injury, is one ... neurological damage among infants and children. This can happen ...
... La Jolla, Calif., June 30, 2008--In a breakthrough scientific ... National Academy of Sciences , scientists at the Burnham ... cell development may be linked to Autism. The study ... (MEF2C) protein in neural stem cells had smaller brains, ...
... The dream of personalized medicine in which diagnostics, risk ... profile may be on the verge of being expanded ... of researchers with the U.S. Department of Energy,s Lawrence Berkeley ... DNA or RNA assays the key to genetic profiling ...
Cached Biology News:Resuscitation technique after brain injury may do more harm than good 2Researchers link early stem cell mutation to autism 2New electrostatic-based DNA microarray technique could revolutionize medical diagnostics 2New electrostatic-based DNA microarray technique could revolutionize medical diagnostics 3New electrostatic-based DNA microarray technique could revolutionize medical diagnostics 4
... is a four-channel general purpose laboratory amplifier. It ... sources which may have a large common-mode level ... a high gain/low noise amplifier, an input coupling ... offset control. A control knob sets the amplifier ...
... Pro-OpioMelanoCortin (POMC) has long been a ... precursor to a multiplicity of biologically-active ... -endorphin, Alpha-Melanocyte Stimulating Hormone (a-MSH) and ... well-conserved molecule, being found in most ...
...
...
Biology Products: